Key facts
- It has raised $1.9M across 1 recorded rounds; the latest was Accelerator/Incubator in Jun 2025.
- Notable investors include MedTech Innovator, Duke Capital Partners, 2ndF, Harbright Ventures, North Carolina Biotechnology Center — 6 tracked in total.
- VQ Biomedical has filed 1 Form D with the SEC, most recently Mar 2025 ($1.6M sold to 21 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for VQ Biomedical
Funding rounds
1 roundsAbout VQ Biomedical
Developer of novel technologies designed for safely delivering oxygen to patients independently of diseased lungs. The company offers a transformative approach to respiratory support and its catheter intends to achieve oxygenation without requiring the patient's blood to be pumped outside the body, ensuring a safer, more efficient and less invasive solution, enabling patients with respiratory failure to get supplemental oxygen to rest, heal and recover.
- Sector
- Healthcare
- HQ
- Apex, NC, United States
- Founded
- 2023
- Employees
- 8
- Website
- vqbiomedical.com/
- Ownership
- Privately Held (backing)
VQ Biomedical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in VQ Biomedical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on VQ Biomedical in its N-PORT filings yet. We sweep new filings monthly.